Premarket weakness in Celsion (CLSN) is attributed to a TheStreet.com article suggesting taking...

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Premarket weakness in Celsion (CLSN) is attributed to a TheStreet.com article suggesting taking profits ahead of Jan. trial results for its ThermoDox drug candidate for treatment of primary liver cancer. Also, CLSN shares have more than doubled since mid-November. CLSN -6.9% premarket.